Trial reportIn vivo (Athens, Greece)
Short-term Efficacy of Botulinum Toxin A for Refractory Overactive Bladder in Female Patients.
Trial report in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Does Injection Number Matter? A Systematic Review and Meta-Analysis of Bladder Botox for Overactive Bladder.International urogynecology journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimThis study aimed to assess the effectiveness and safety of 100 U onabotulinumtoxinA (also known as botulinum toxin type A) for overactive bladder (OAB) and urgency urinary incontinence (UUI) in Japanese women. PATIENTS AND
methodsThis prospective, nonrandomized study was conducted as a single-center clinical trial in Japan and targeted patients with OAB that did not respond adequately to standard treatments, including anticholinergics and β3-adrenergic receptor agonists. A total of 26 patients received a single intradetrusor injection of onabotulinumtoxinA. The primary endpoint was the change in the number of daily UUI episodes between baseline and week 12. The secondary endpoints were improvements in other OAB symptoms and health-related quality of life (HRQoL). Adverse events were monitored.
resultsPatients who received onabotulinumtoxinA experienced a significant reduction in the mean number of daily UUI episodes between baseline and week 12 (-3.49;
conclusionOnabotulinumtoxinA administered at a dose of 100 U was well-tolerated and resulted in significant and clinically meaningful improvements in the OAB symptoms and HRQoL of patients whose OAB could not be adequately managed with other treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.